objective To assess mortality and clinical outcomes in children treated with antiretroviral therapy (ART) in four African vertical programmes between 2001 and 2010.
Introduction
Only 32% of HIV-positive children in need of antiretroviral therapy (ART) receive it, vs. 41% of adults in 2014 [1] . National HIV programmes and health providers in resource-limited countries face important challenges. Access to HIV testing and care in rural and in deprived urban areas is particularly challenging and inequitable [2, 3] . Not enough trained staff, supervision and diagnostic tools, plus drug stock-outs and high costs associated with care provision, lead to delays in care access and suboptimal care quality. In 2013, WHO recommended that children aged <5 years initiate ART immediately after diagnosis of HIV infection, and since 2015, ART initiation upon diagnosis is recommended for children of all ages [4] . Early paediatric diagnosis relies on virological testing, but its availability and integration with prevention of mother-to-child transmission (PMTCT) services and non-PMTCT child health services remain insufficient in many resource-limited settings. In the absence of treatment, 53% of children die before their second birthday [5] , while late start of treatment is associated with poor treatment outcomes.
Once diagnosed and on treatment, children remain particularly vulnerable due to their dependence on adults to be diagnosed and to obtain adequate and regular treatment. Continuous family support is often lacking due to death or sickness of caregivers. Furthermore, the need to adjust drug doses to the changing weight of children [6] and lack of adequate paediatric formulations may lead to inadequate dosing [7] and ultimately increase the risk of virological failure and acquisition of drug resistance [7, 8] .
To evaluate the first 10 years of experience in treating paediatric HIV infection in four HIV programmes in Malawi, Uganda and Kenya, we describe the characteristics of children started on ART and compared age-specific patient outcomes after the first two years of ART start.
Methods

HIV programmes
In the early 2000s, M edecins Sans Fronti eres (MSF), in partnership with the Ministries of Health, started providing free medical HIV care in a non-governmental clinic of one of the urban slums of Nairobi (Kenya), in the regional referral hospital of Arua (Uganda), in a highly decentralized programme in a rural district in Chiradzulu (Malawi) and in the rural district of Homa-Bay (Kenya). Free medical services provided include HIV counselling and testing, PMTCT care, laboratory investigations, the management of opportunistic infections, ART and hospitalisation. Eligibility criteria for ART initiation are based on WHO recommendations for scaling up ART in lowresource settings. Children aged >18 months are diagnosed after obtaining two positive rapid antibody test results. Younger children are diagnosed through proviral DNA polymerase chain reaction tests performed on dried blood spots. Most children included in this analysis had received adult stavudine-based formulations. Paediatric fixed-dose combination drugs were provided after WHO prequalification (July 2007). Daily cotrimoxazole prophylaxis was prescribed.
Children were clinically examined at least monthly during the first 6 months of ART use and then every 2-3 months after clinical stabilization. Adherence counselling focused on parental/caregiver education, although initiatives to progressively involve children as they became older were gradually implemented. CD4 cell counts were measured before ART initiation and ever 6-12 months thereafter. No viral load monitoring was implemented, but, since 2008, viral load testing was gradually introduced to confirm suspicion of clinical or immunological failure. Patients who started ART between December 2001 and December 2010 in one of the study sites were aged <15 years at the date of treatment initiation, had more than one follow-up visit and had been registered 1 year or more before December 2011 were included in the analysis.
Data collection and study population
Study definitions
WHO standards for weight-for-age Z-scores were used, and children underweight was defined as a weight-forage score of <À2 in children of <5 years, or an ageand sex-specific body mass index (BMI) value equivalent to the <18.5 cut-off points for adults in 5-14-year-old children [9, 10] . The nadir immunosuppression level was estimated as the lowest CD4 cell percentage (age <2) or count (age 2-14) [11] , among measurements recorded within 3 months before and 12 months after ART initiation. Nadir immunosuppression was classified as severe (CD4 per cent <15% or count <200 cells/ll), moderate (CD4 per cent of 15-24% or count of 200-350 cells/ll), or absent (CD4 per cent >25% or count of >350 cells/ll).
Children with history of PMTCT drug use were those whose mothers had recorded use of PMTCT prophylaxis during pregnancy/labour/delivery and/or those who had recorded prescription of PMTCT prophylaxis after birth.
For each patient, first-line treatment failure was defined as the earliest clinical, immunological or virological failure event [12] . Clinical failure was a recorded diagnosis of a recurrent or a new WHO clinical stage 3 or 4 condition after 6 months of first-line use. Immunological failure was defined as a decline in CD4 cell count or percentage to baseline value or below; a decline of ≥50% from the highest on-treatment measurement after 6 months of therapy, in CD4 cell count or percentage; or a CD4 cell count below 100 cells/ll after 1 year of therapy. Virological failure was a plasma HIV viral load value of more than 5000 copies/ml after 6 months of ART.
The dates of follow-up appointments for each patient enrolled in the HIV clinics are recorded in the electronic health record system of the programmes. For patients receiving ART, these appointments are generally scheduled monthly. For the purpose of the study, a child was considered lost to follow-up (LTFU) if the last scheduled appointment was missed for ≥2 months or, when no date of next appointment was specified, if he/she did not attend the clinic for ≥6 months. Attrition was defined as a composite endpoint of death or LTFU. Children who attended <5% of their appointments with delay were considered 95% or more adherent, those with 5-9% of delayed appointments were considered 90-94% adherent and those with 10% or more delayed appointments were considered <90% adherent to therapy [13, 14] .
Statistical analysis
Patient characteristics at ART initiation were described by age group (<2, 2-4 and 5-14 years) and by period of treatment start. For longitudinal analyses, patient followup was right-censored at the earliest of the following dates: event (death or failure diagnosis), last clinic visit (for patients LTFU), transfer outside the programme or 1 year after ART start for children aged <2 years old and 2 years after ART start for children ≥2 years old for non-FTFU patients. Rates of mortality, attrition and first-line failure were calculated as the number of events per 100 person-years of follow-up. Risk factor analyses were performed using adjusted Cox proportional hazard models (mortality) and Poisson's regression (attrition and treatment failure). Factors considered for adjustment included the following: study site, mode of entry and sex; age group, clinical stage, underweight (binary indicator) and tuberculosis diagnosis at ART start; year of ART initiation (2001-2004, 2005-2007 and 2008-2010) ; nadir immunosuppression level and adherence index. For the attrition analysis, temporal changes in attrition rates after the start of ART were studied after splitting patient follow-up into ≤3, 4-6 and 7-24 months. Final models were adjusted for baseline characteristics associated with the outcomes in univariable analyses (P < 0.2) and for gender and study site. Missing covariate data were included as a separate category. The fit of the final models was assessed with the goodness-of-fit test.
A sensitivity analysis was performed including only patients with complete case data. All analyses were performed with Stata 11 (Stata Corp, USA).
Results
Patient characteristics
A total of 3949 HIV-infected children who initiated ART between December 2001 and December 2010, and had more than one medical visit recorded, were included ( Figure 1) ; 50% of children were females, 897 (22.7%) were aged <2 years and 1780 (45.1%) aged ≥5 years at ART initiation ( Table 1 (Table S1 ). Baseline characteristics were generally similar across the three age groups. The primary modes of entry in the programme were through voluntary counselling and testing services (48.0%) and medical referral 
Mortality and programme attrition by age group
During the 5858 person-years of follow-up, 299 (7.6%) children died and 337 (8.5%) were LTFU. The median time between ART initiation and death was 6.5 months (IQR 2.0-15.9), and it was longer for the 2-4-year group than for other age groups (8.5 months, IQR = 2.0-29.1; compared to 7.0 months, IQR = 2.3-15.4 among <2-year-olds, and 5.3 months, IQR = 1.9-12.3 in the 5-14-year group). The overall mortality rate was 5.1 (95% CI 4.6-5.7) per 100 person-years and 1.1 per 100 person-years (95% CI 0.7-1.6) in the second year of ART use. Mortality decreased over time from 14.3 per 100 person-years (95% CI 12.1-16.9) during the first three months of therapy to 2.6 per 100 person-years (95% CI 2.1-3.2) after 6 months of ART use ( Figure 2 and Table 2 ). The overall attrition rate was 10.8 (95% CI 10.0-11.7) per 100 person-years and, as for mortality, attrition declined from 25.4 per 100 person-years (95% CI 22.4-28.8) during the first three months of therapy to 6.8 per 100 person-years (95% CI 6.1-7.7) after 6 months of ART use (Table 2) .
Crude rates of mortality were higher among the youngest children (12.1 per 100 person-years, 95% CI 9.9-14.9, compared to 2.9 per 100 person-years, 95% CI 2.3-3.7, in the 2-4-year group and 4.8 per 100 personyears, 95% CI 4.1-5.7, in the 5-14-year group; Table 2 ). 
Risk factors for mortality and programme attrition
The presence of severe immunosuppression (HR = 2.69, 95% CI 1.77-4.10), underweight (HR = 2.02, 95% CI 1.57-2.61) and advanced clinical disease (HR = 1.58, 95% CI 1.11-2.24 for stage 4 compared to stages 1 or 2) was all factors associated with increased mortality (Table 2 ). Children diagnosed with tuberculosis had also increased mortality (HR = 1.43, 95% CI 1.06-1.91). The same associations were identified when complete case analyses were performed. The exception was in clinical stage 4, which was no longer significantly associated with increased mortality in the complete case analysis. Furthermore, estimates for the calendar year period of ART initiation were inconsistent, with higher mortality hazards being observed for children who started therapy during the earliest period (2001-2004 vs. 2008-2010) in complete case analyses. Programme attrition was also more common in children with severe clinical disease (IRR = 1.65, 95% CI 1.30-2.09 for stage 4 compared to stages 1 or 2), underweight (IRR = 1.65, 95% CI 1.40-1.95) and moderate and severe immunosuppression (IRR = 1.57, 95% CI 1.17-2.10 and IRR = 1.87, 95% CI 1.44-2.44, respectively, compared to the absence of immunosuppression). It was also higher during the first 3 months of follow-up (IRR = 2.49, 95% CI 2.08-2.99 for 0-3 months; and IRR = 1.51, 95% CI 1.21-1.88 for 4-6 months, compared to 7-24 months post-ART initiation). Complete case analyses identified the same risk factors (Table 2) .
Treatment failure by age group
During the study period, children contributed 5369 person-years of follow-up to the treatment failure analysis and 484 (12.2%) children were diagnosed with ART Figure 2c ). Rates decreased over time to 8.6 per 100 years (95% CI 6.9-10.9) in the 12-24-month period for children aged 2-4 years and to 9.8 per 100 person-years (95% CI 8.2-11.8) in 5-14-year-olds.
Risk factors for treatment failure
Female patients were less frequently diagnosed with treatment failure than males (IRR = 0.75, 95% CI 0.62-0.89; Table 3 ). In contrast, increased proportion of failure was observed in children starting ART with advanced clinical disease (IRR = 1.37, 95% CI 1.04-1.80 for stage 4 compared to stages 1 or 2), underweight (IRR = 1.35, 95% CI 1.12-1.63) and severe nadir immunosuppression (IRR = 1.67, 95% CI 1.33-2.11). Patients with lower adherence index (higher proportion of missed visits over the time of follow-up) were also more likely to be diagnosed with failure (IRR = 1.69, 95% CI 1.27-2.24 for <80% compared to ≥95% adherence). Furthermore, higher IRRs were also observed among children who started ART in the earlier calendar period (IRR = 1.64, ART, antiretroviral therapy; CI, confidence interval; IRR, incidence rate ratio; LTFU, lost to follow-up.
95% CI 1.26-2.12 compared to [2008] [2009] [2010] . Analysis restricted to patients with complete case data identified the same associations, except for females, for whom this relationship was no longer significant.
Discussion
In this study, we report patient characteristics and good treatment outcomes of a large cohort of children infected with HIV who started therapy during the first decade of paediatric ART provision in four HIV programmes in Kenya, Uganda and Malawi. Overall, children started ART late and many with advanced clinical disease. However, the median age at ART start decreased by half over time (from six years [15] . One reason for these changes is likely related to changes in the WHO recommendations for paediatric care, which recommended ART 'as soon as signs of advanced HIV disease developed' [16, 17] . With increasing evidence of the benefit of early ART initiation in infancy [18] [19] [20] , guidelines were updated to recommend therapy immediately after HIV diagnosis, regardless of clinical and immunological status to younger age children (in 2010 for children between 1 and 2 years [11] , in 2013 to children below five [21] and since 2015 to all independent of age [4] ). Another key factor contributing to delayed paediatric ART initiation is the limited or lack of access to virological testing for early infant diagnosis inside and outside PMTCT programmes (e.g. in malnutrition wards [22, 23] ). By the end of 2013, the estimated percentage of HIV-exposed infants who benefited from virological testing within two months of birth was only 42% in Kenya, 36% in Uganda and 15% in Malawi [23] .
Despite late start of treatment, 2-year mortality rates (5.1 per 100 person-years) were good and similar to estimates reported in other sub-Saharan African and SouthEast Asian programmes [24] [25] [26] [27] [28] [29] [30] [31] [32] . Lower death rates have been reported in Thailand (1.3 deaths/100 person-years) [33] , and higher estimates in rural Mozambique, where 39% LTFU and 29% death after 2 years on ART were reported among 735 children [34] . Comparisons of mortality across settings are, however, problematic, due to disparities in undocumented deaths. In a study conducted in our programme of Chiradzulu, half of the children initiated on ART and LTFU had died [35] , and in our study, LTFU and death rates were of similar size, resulting in an attrition rate of 10.8 per 100 person-years.
In agreement with other studies [24, 25, 27, 29, 32, 36, 37] , we found an increased risk of death and attrition in children with advanced HIV disease (defined by clinical stage, immunosuppression, tuberculosis or underweight). Irrespective of age at therapy start, failure estimates were highest within the first 3 months post-ART, highlighting the need for close monitoring during this critical stage. Some studies identified young age at ART start (younger than 6-18 months) as a risk factor for mortality [29, 31, [36] [37] [38] [39] [40] [41] . In our analysis, crude mortality was four times higher amongst children of <2 years and about twice as high in 2-4-year-olds compared to the older group. However, in adjusted analyses the lowest mortality was observed in the 2-4-year group. This might result from a combination of the early death of vulnerable younger undiagnosed children [42] , an increasing risk associated with longer exposure to HIV in older surviving children who did not benefit from adequate PMTCT prophylaxis and were diagnosed late in the course of HIV infection, and the difficulties to maintain good treatment adherence in the eldest children, which depends on full disclosure status, acceptance of the disease and a supporting environment during the adolescent period.
About one of eight children (12.2%) met treatment failure criteria during follow-up and no age differences in rates were observed. However, rates are likely to have been underestimated, as failure was essentially defined by immunological and clinical criteria, which are known to be inaccurate [43] [44] [45] [46] , and viral load testing was only available for a small proportion of children. Previously reported 2-3-year virological failure rates in paediatric populations range from 14% in Cambodia [47] to 38% in rural South Africa [8] , and a meta-analysis of studies conducted in resource-limited settings reported a pooled virological failure estimate of 30% after 1 year of ART among <18-year-olds [48] . Current efforts to roll out access to routine viral load monitoring are expected to improve timely detection of paediatric ART failure [49] and to permit a more accurate evaluation of the effectiveness of paediatric treatment programmes.
In our analysis, treatment failure was more frequent in children with advanced HIV disease and during the first 6-12 months of treatment, emphasising the importance of early ART initiation, careful monitoring and adherence support during the first months of treatment. Children who started ART in later periods (2008-2010) had lower failure rates, which are likely related to improvements in clinical management and access to paediatric formulations over time.
In the present study, many children were initially underweight and had a higher risk of mortality, LTFU and treatment failure. Underweight and/or malnutrition are known risk factors of mortality in HIV-infected children [24, 25, 32, 50, 51] , and systematic initial and regular monitoring of nutrition status at ART initiation is recommended [21] . Tuberculosis is another serious threat for HIV-infected children and an important cause of death [52, 53] . Unfortunately, paediatric tuberculosis diagnosis is difficult, largely based on clinical symptoms and often presumptive. The percentage of children with tuberculosis at ART start in our study is therefore likely to be underestimated. Nevertheless, we found clear evidence of increased mortality in children with tuberculosis. Systematic screening for tuberculosis and timely start of prophylaxis treatment are also important to prevent paediatric deaths.
This study provides real-world estimates of treatment outcomes achieved during the first decade of paediatric ART provision under programmatic conditions in four large MSF-supported HIV programmes in sub-Saharan Africa. It included nearly 4000 children of different age groups with a balanced sex distribution. Besides the limitations already discussed, it is important to note that the risk factor analysis could only consider patient characteristics and clinical data routinely collected for patient care and programme monitoring in the HIV registry. No information was available on reason for LTFU or the proportion of deaths amongst children LTFU, and analyses were not adjusted for characteristics of health facilities. Furthermore, our data were limited to 2 years of paediatric ART follow-up. Analysis and reporting of longer-term outcomes, especially for infants who have benefited from greater access to early infant diagnosis and diagnostic tools and to treatment with paediatric ART formulations in recent years, are therefore needed.
Conclusion
Despite late presentation and relatively advanced age at ART start, the good paediatric outcomes observed after 1-2 years of ART use demonstrate that paediatric ART provision can be feasible and effective in resource-limited settings. Our findings indicate that early ART start, before signs of clinico-immunological deterioration appear, might be beneficial for children of all age groups and that close monitoring during the first months of therapy is critical to improve paediatric care.
